Literature DB >> 20633319

Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine.

Bodil Aggernaes1, Birte Y Glenthoj, Bjorn H Ebdrup, Hans Rasmussen, Henrik Lublin, Bob Oranje.   

Abstract

Impaired prepulse inhibition of the startle reflex (PPI) in schizophrenia has been replicated in many studies. However, previous results may have been influenced by course of illness, and antipsychotic medication. Studies on antipsychotic-naive, first-episode schizophrenia patients are lacking, since these patients are so difficult to recruit. Furthermore, longitudinal studies are few, and their results are inconsistent: some results indicating a reduction of PPI deficits by treatment with atypical antipsychotics, while others do not. This study reports on PPI, habituation and sensitization of the human startle reflex in a large group of antipsychotic-naive, first-episode schizophrenia patients, and the effect of subsequent treatment with quetiapine. Thirty-four antipsychotic-naive, first-episode schizophrenia patients (24 males, 10 females), and age- and gender-matched healthy controls were tested in a psychophysiological test battery at baseline and again after 6 months. During this period, the patients were treated with quetiapine, while the controls received no treatment. Sixteen patients completed the study. At baseline, male patients showed significantly lower PPI than controls. Treatment with quetiapine for 6 months increased male PPI to a level where it was no longer statistically different from the controls. The much smaller group of females did not show PPI deficits at baseline. In addition, compared to controls, patients appeared highly aroused and showed a strong yet non-significant trend for reduced sensitization at baseline, but not at follow-up. Patients and controls showed similar levels of habituation, both at baseline, and at follow-up. These findings indicate that PPI deficits are already present from the earliest stage of clinical onset of schizophrenia, before the patients have received any antipsychotic treatment. In addition, following 6 months' treatment with quetiapine these PPI deficits were normalized. Furthermore, the results suggest that schizophrenia patients in the antipsychotic-naive state show reduced levels of sensitization, yet normal levels of habituation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20633319     DOI: 10.1017/S1461145710000787

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  19 in total

1.  Persistent gating deficit and increased sensitivity to NMDA receptor antagonism after puberty in a new mouse model of the human 22q11.2 microdeletion syndrome: a study in male mice.

Authors:  Michael Didriksen; Kim Fejgin; Simon R O Nilsson; Michelle R Birknow; Hannah M Grayton; Peter H Larsen; Jes B Lauridsen; Vibeke Nielsen; Pau Celada; Noemi Santana; Pekka Kallunki; Kenneth V Christensen; Thomas M Werge; Tine B Stensbøl; Jan Egebjerg; Francois Gastambide; Francesc Artigas; Jesper F Bastlund; Jacob Nielsen
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

2.  Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients.

Authors:  Signe Düring; Birte Y Glenthøj; Gitte Saltoft Andersen; Bob Oranje
Journal:  Neuropsychopharmacology       Date:  2014-07-23       Impact factor: 7.853

3.  Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS.

Authors:  Neal R Swerdlow; Gregory A Light; Joyce Sprock; Monica E Calkins; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Keith H Nuechterlein; Allen D Radant; Amrita Ray; Larry J Seidman; Larry J Siever; Jeremy M Silverman; William S Stone; Catherine A Sugar; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff
Journal:  Schizophr Res       Date:  2014-01-07       Impact factor: 4.939

Review 4.  Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models.

Authors:  D Sinclair; B Oranje; K A Razak; S J Siegel; S Schmid
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

5.  Meta-Analysis of Sensorimotor Gating Deficits in Patients With Schizophrenia Evaluated by Prepulse Inhibition Test.

Authors:  Rodrigo San-Martin; Leonardo Andrade Castro; Paulo Rossi Menezes; Francisco José Fraga; Priscyla Waleska Simões; Cristiane Salum
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

6.  Association Study of CHRNA7 Promoter Variants with Sensory and Sensorimotor Gating in Schizophrenia Patients and Healthy Controls: A Danish Case-Control Study.

Authors:  Birgitte Bertelsen; Bob Oranje; Linea Melchior; Birgitte Fagerlund; Thomas M Werge; Jens D Mikkelsen; Zeynep Tümer; Birte Y Glenthøj
Journal:  Neuromolecular Med       Date:  2015-09-16       Impact factor: 3.843

7.  Structural brain correlates of sensorimotor gating in antipsychotic-naive men with first-episode schizophrenia.

Authors:  Trine Bjørg Hammer; Bob Oranje; Arnold Skimminge; Bodil Aggernæs; Bjørn H Ebdrup; Birte Glenthøj; William Baaré
Journal:  J Psychiatry Neurosci       Date:  2013-01       Impact factor: 6.186

8.  Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population.

Authors:  Kristin S Cadenhead
Journal:  Psychiatry Res       Date:  2011-05-08       Impact factor: 3.222

9.  Clonidine normalizes levels of P50 gating in patients with schizophrenia on stable medication.

Authors:  Bob Oranje; Birte Y Glenthøj
Journal:  Schizophr Bull       Date:  2013-10-08       Impact factor: 9.306

10.  Affect modulated startle in schizophrenia: subjective experience matters.

Authors:  Rachelle M Dominelli; Jennifer M Boggs; Amanda R Bolbecker; Brian F O'Donnell; William P Hetrick; Colleen A Brenner
Journal:  Psychiatry Res       Date:  2014-07-09       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.